tiprankstipranks
Trending News
More News >
Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
India Market
Advertisement

Balaxi Pharmaceuticals Limited (BALAXI) Price & Analysis

Compare
0 Followers

BALAXI Stock Chart & Stats

₹41.12
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹41.12
-₹2.28(-2.93%)

BALAXI FAQ

What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹40.76 and its highest was ₹98.00 in the past 12 months.
    What is Balaxi Pharmaceuticals Limited’s market cap?
    Balaxi Pharmaceuticals Limited’s market cap is ₹454.03M.
      When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
      Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Oct 31, 2025 which is in 10 days.
        How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
        Balaxi Pharmaceuticals Limited released its earnings results on Aug 05, 2025. The company reported ₹0.263 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.263.
          Is Balaxi Pharmaceuticals Limited overvalued?
          According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Balaxi Pharmaceuticals Limited pay dividends?
            Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
              What is Balaxi Pharmaceuticals Limited’s EPS estimate?
              Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Balaxi Pharmaceuticals Limited have?
              Balaxi Pharmaceuticals Limited has 11,041,500 shares outstanding.
                What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
                Balaxi Pharmaceuticals Limited reported an EPS of ₹0.263 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.027%.
                  Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
                  Currently, no hedge funds are holding shares in IN:BALAXI

                  Company Description

                  Balaxi Pharmaceuticals Limited

                  Balaxi Pharmaceuticals Limited (BALAXI) is a rapidly growing pharmaceutical company that operates in the generic pharmaceutical sector. The company is primarily focused on the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription and over-the-counter medications. Balaxi Pharmaceuticals emphasizes expanding its presence in emerging markets, leveraging its robust product portfolio and strategic distribution networks to meet the healthcare needs of diverse populations.

                  Balaxi Pharmaceuticals Limited (BALAXI) Earnings & Revenues

                  BALAXI Stock 12 Month Forecast

                  Average Price Target

                  ₹48.00
                  ▲(16.73% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"₹44","75":"₹75","106":"₹106","59.5":"₹59.5","90.5":"₹90.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,59.5,75,90.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.79,45.96,46.13,46.3,46.47,46.64,46.81,46.98,47.15,47.32,47.49,47.66,47.83,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.79,45.96,46.13,46.3,46.47,46.64,46.81,46.98,47.15,47.32,47.49,47.66,47.83,{"y":48,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.79,45.96,46.13,46.3,46.47,46.64,46.81,46.98,47.15,47.32,47.49,47.66,47.83,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.38,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":89.95,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":81.35,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":72,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67.91,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.3,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.99,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":55.16,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.04,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50.01,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50.01,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.36,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.79,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Biofil Chemicals & Pharmaceuticals Ltd.
                  Gkb Ophthalmics Limited
                  Ind-Swift Ltd.
                  Lasa Supergenerics Ltd.
                  Vivimed Labs Limited
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis